Giant Biogene's 2024 Profit Jumps 42%; EPS, Revenue Top Estimates
Giant Biogene's (HKG:2367) attributable profit rose 42% to 2.06 billion yuan in 2024 from 1.45 billion yuan in 2023, according to a Wednesday filing with the Hong Kong bourse.
Earnings per share at the skincare products maker increased 39% to 2.06 yuan from 1.48 yuan a year earlier. Analysts at Visible Alpha estimated EPS at 2.04 yuan.
Revenue grew 57% to 5.54 billion yuan from 3.52 billion yuan in the previous year. Visible Alpha analysts forecast revenue at 5.26 billion yuan.
The company declared a final dividend of 0.6021 yuan per share and a special dividend of 0.5921 yuan per share, both payable Aug. 29 to shareholders on record as of June 24.
Shares rose 1% during Thursday's trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available